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astrocytes promote the efficient generation of
motor neuron progenitors from mouse
embryonic stem cells
Yiota A Christou1*, Kyoji Ohyama3, Marysia Placzek3, Peter N Monk2† and Pamela J Shaw1†Abstract
Background: The efficient derivation of mature (Hb9+) motor neurons from embryonic stem cells is a sought-after
goal in the understanding, and potential treatment, of motor neuron diseases. Conditions that promote the robust
generation of motor neuron progenitors from embryonic stem cells and that promote the survival of differentiated
motor neurons ex vivo are likely, therefore, to be critical in future biological/therapeutic/screening approaches.
Previous studies have shown that astrocytes have a protective effect on differentiated motor neurons (in vivo and
ex vivo), but it remains unclear whether astrocytes also play a beneficial role in the support of motor neuron
progenitors. Here we explore the effect of murine astrocyte-conditioned medium on monolayer cultures of mouse
embryonic stem cell-derived motor neuron progenitors.
Results: Our data show that wild-type astrocyte-conditioned medium significantly increases the number of
Olig2+/Hb9- progenitors, which subsequently differentiate into Hb9+/Islet1+ post-mitotic motor neurons.
Intriguingly, while astrocyte-conditioned medium derived from mice transgenic for wild-type human SOD1 mimics
the effect of wild-type astrocytes, conditioned medium derived from astrocytes carrying an amyotrophic lateral
sclerosis-related SOD1-G93A mutation shows no such beneficial effect. The effect of astrocyte-conditioned medium,
moreover, is specific to motor neurons: we find that interneurons generated from mouse embryonic stem cells are
unaffected by conditioned media from any type of astrocyte.
Conclusions: Our study indicates that conditioned medium derived from wild type astrocytes enhances the
efficient generation of motor neurons from mouse embryonic stem cells by enhancing motor neuron progenitors.
In contrast, conditioned medium from SOD1-G93A astrocytes does not show a similar enhancing effect.
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Motor neurons (MNs) are selectively depleted, or dimin-
ished, in motor neuron diseases such as amyotrophic
lateral sclerosis (ALS). Various factors contribute to the
pathogenesis of ALS including mutations in the SOD1
gene, mutations in the ALS2 (Alsin) [1,2], FUS (RNA-bind-
ing protein FUS) [3],TARDBP (TAR DNA-binding protein
43) [4,5], ATXN2 (Ataxin-2) [6] and ANG (Angiogenin) [7]* Correspondence: yiotachrist17@hotmail.com
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reproduction in any medium, provided the orgenes, and the recently-discovered intronic hexanucleotide
expansions in C9ORF72 [8,9]. In mutant SOD1 disease
models, non-neuronal cells, such as astrocytes have been
implicated in the pathogenesis of MN degeneration
[10-12]. The mechanism by which astrocytes facilitate MN
loss has not yet been fully identified, but a number of po-
tential mechanisms have been reported. The production
of NGF (nerve growth factor) (or related species such as
NGF-precursor forms (pro-NGF)) in reactive SOD1-
G93A (change of alanine to glycine at position 93 of the
SOD1 protein) astrocytes can induce death of rat MNs ex-
pressing p75-receptor, through a mechanism that involvesl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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creased secretion of pro-NGF and subsequent induction of
toxic p75 receptor signalling within neighbouring motor
neurons is believed to be a key element of the toxicity of
mutant SOD1-expressing astrocytes to motor neurons
[14]. Studies in mouse have similarly shown that astrocytes
expressing mutant forms of SOD1-G37R (change of argin-
ine to glycine at position 37), SOD1-G85R (change of ar-
ginine to glycine at position 85), and SOD1-G93A (change
of alanine to glycine at position 93), release soluble factors
that can selectively kill embryonic stem (ES) cell-derived or
primary MNs in vitro, and have demonstrated that neuro-
toxicity by SOD1-G93A astrocytes is mediated through
the recruitment of the Bax-dependent death machinery. By
contrast, conditioned medium from wild-type SOD1-
expressing astrocytes displays a supportive/survival effect
on MNs similar to that observed with non-transgenic
astrocytes [15]. Co-culture of ES cell-derived MNs with
SOD1-G93A astrocytes markedly decreases MN survival
relative to primary wild-type SOD1 astrocytes [16]. In vivo,
the transplantation of glial-restricted precursor cells into
the vicinity of cervical spinal cord respiratory MNs in a
SOD1-G93A rat model of motor neuron disease limits pro-
gression of the disease, resulting in enhanced motor and
respiratory physiological functions and enhanced survival
[17]. The neuroprotective effects have been partly attrib-
uted to increased expression of the astrocytic glutamate
transporter, GLT1. Taken together, the evidence from these
studies suggests that astrocytes are critically involved in
MN depletion in ALS, most likely acting through multiple
mechanisms.
As yet, no study has examined whether astrocytes exert
an effect on MN-progenitor cells. Two factors suggest this
is an important question. First, the efficient derivation
of mature (Hb9+) MNs from embryonic stem cells is a
sought-after goal in the understanding, and potential treat-
ment, of motor neuron diseases: factors that enhance early
steps in MN differentiation will therefore contribute to
the derivation of MNs ex vivo. Second, the realisation that
new neurons can be generated within the adult brain sug-
gests the possibility that ALS-driven MN depletion may
result from the loss of adult-born neurons. Recent experi-
ments in songbirds show that adult neurogenesis can
result in the addition of new neurons to cortical premotor
circuits that govern peripheral muscle control [18], while
dopamine produced by projections of the brain promotes
adult MN regeneration in lesioned spinal cord in zebrafish
[19], supporting this idea. Thus, we aimed to extend
current knowledge by examining the potential effect of as-
trocytes on MN progenitors. Here we show that wild-type
astrocyte-conditioned medium promotes the efficient
generation of MN progenitors from mouse ES cells. By
contrast, SOD1-G93A astrocytes are less supportive for
the generation of these MN progenitors.Results
Spatio-temporal expression profiles of transcription
factors in MN development in mouse neural tube
As a basis for monitoring MN differentiation from mouse
ES cells in vitro, we first examined the expression profiles
of the transcription factors Olig2, Hb9/MNR2 and Islet1
in the embryonic mouse neural tube at E10.5; all have
been previously demonstrated to be involved in MN fate
determination [20-22].
As previously shown [20-22], Olig2 expression is re-
stricted to the ventral neural tube, demarcating progenitor
domain (p)V3 and (p)MN (Figure 1). By contrast, Hb9/
MNR2 expression is restricted to differentiated MNs in
the mantle zone of the emerging spinal cord (Figure 1).
Consistent with this, double labelling of Hb9/MNR2 with
Ki67, a marker of proliferating cells, reveals no overlap,
confirming that Hb9/MNR2 is a marker for post-mitotic
MNs (Figure 1). Double-labelling for Olig2 and Hb9/
MNR2 reveals that the majority of Olig2+ cells do not
co-express Hb9/MNR2 and are largely restricted to the
ventricular zone and subventricular zone (VZ/SVZ), the
region of the developing neural tube that harbours prolif-
erating progenitor cells. A small proportion of Olig2+ cells
(8.47%) were Hb9/MNR2+. These Olig2+/Hb9+ cells were
found furthest from the VZ/SVZ, and represent a popula-
tion of Olig2+ cells that are making their transition to-
wards Hb9/MNR2+ differentiating MNs as they migrate
away from the medial VZ to the peripheral mantle zone
(Figure 1). Similarly, a few Olig2+/Islet1+ cells were located
away from the VZ/SVZ and were detected immediately
adjacent to Olig2-/Islet1+ differentiated MNs (Figure 1).
Taken together, our data confirm previous reports [23,24],
showing that many Olig2+ cells are proliferating MN pro-
genitor cells. These analyses suggest, further, that the
combinatorial analysis of Olig2, Hb9/MNR2 and Islet1
expression can be used as a basis for monitoring the differ-
entiation status of MNs from mouse ES cells.
Wild-type but not mutant SOD1-G93A astrocyte-conditioned
medium promotes the generation of MN progenitors from
mouse ES cells and subsequent MN differentiation
The effect of conditioned medium (CM) from cultured
wild-type non-transgenic (wt non-Tg) astrocytes on differ-
entiated MNs was first assessed, in comparison to control
medium (not conditioned by astrocytes). MN differenti-
ation was assessed through Hb9:eGFP reporter activity
and further confirmed by co-expression of either β3-
tubulin or Islet1. Hb9:eGFP+ MNs co-expressed β3-
tubulin (Figure 2a,b; white arrows: 100% co-expression,
data not shown) and Islet1 (Figure 2e-g; white arrows:
95.03% co-expression, data not shown). Quantitative ana-
lyses showed that culture with wt non-Tg astrocyte CM
resulted in a marked increase in MNs. The percentage of
eGFP+ MNs was increased by a fold-change of 2.8,
Figure 1 Motor neuron development in embryonic mouse neural tube. Fluorescence images of embryonic (E10.5) mouse neural tube, after
immunolabelling for Olig2 (green), Islet1 (red), Hb9/MNR2 (red), Ki67 (green) and DAPI for nuclei (blue). Scale bars 50 μm. The schematic of the
neural tube shows the dorsal (d1-d6) and ventral domains (v0-v3, MN) of the neural tube and corresponding expression markers. RP: roof plate,
FP: floor plate, VZ: ventricular zone, MZ: mantle zone, d: dorsal, v: ventral, MN: motor neuron. Olig2+ cells are restricted to the VZ, the region of
proliferating progenitor cells in the developing neural tube. Islet1+ and Hb9/MNR2+ cells are found at the peripheral mantle zone of the neural
tube representing post-mitotic neurons. A small number of Olig2+/Hb9+ cells, or Olig2+/Islet1+ cells represent progenitor cells that are making
the transition towards Hb9/MNR2+ neurons as they migrate away from the medial VZ to the peripheral MZ.
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with previous findings that wt non-Tg astrocyte CM results
in a highly significant increase in differentiated MNs [15].
To determine whether the increased proportion of dif-
ferentiated MNs might be due, in part, to enhanced num-
bers of progenitors, we analysed expression of the b-HLH
(basic helix-loop helix) transcription factor, Olig2 [20,25].
Many Olig2+ cells were detected within the cultures
(Figure 2a,e). High magnification views after combinatorial
labelling with Olig2, Hb9:eGFP and β3-tubulin, or Olig2,
Hb9:eGFP and Islet1 revealed that the vast majority ofOlig2+ cells did not co-express either β3-tubulin
(Figure 2c,d, red arrows) or Islet 1 (Figure 2h,i, red ar-
rows). Quantitative analyses revealed that only a very
minor proportion of Olig2+ cells co-expressed β3-tubulin
(0.2%) or Islet1 (0.17%) (green arrow, Figure 2e-i). A sig-
nificantly higher percentage of Olig2+ MN-progenitor
cells was detected in cultures grown in wt non-Tg
astrocyte CM, compared to those in control medium
(Figure 2k). Quantitative analyses showed that the per-
centage of Olig2+ MN-progenitors in wt non-Tg astro-
cyte CM was increased by 1.5-fold compared to the
Figure 2 The effect of astrocyte conditioned media on motor neuron-progenitors and motor neurons derived from differentiation of
mouse embryonic stem cells. (a-i) Cultures grown in wt non-Tg astrocyte CM. (a) Immunolabelling for Olig2 (red), Hb9:eGFP (green) and β3-
tubulin (light blue) showing Hb9:eGFP+β3-tubulin+ cells (white arrows) and Olig2+ cells (red arrows). Scale bar 50 μm. (b) High-magnification of
white boxed area in (a), showing co-expression of Hb9:eGFP and β3-tubulin (white arrow). Scale bar 33 μm. (c, d) High-magnification channel
views of red boxed area in (a). Olig2+ cells (red arrows) do not co-express β3-tubulin. Scale bar 20 μm. (e) Immunolabelling for Olig2 (red), Hb9:
eGFP (green), Islet1 (white) and nuclei counterstained with DAPI (blue), showing Hb9:eGFP+Islet1+ cells (white arrows), Olig2+ cells (red arrows)
and Olig2+Hb9:eGFP+Islet1+ cell (green arrow). Scale bar 50 μm. (f-i) High-magnification channel views of white boxed area in (e). MNs show
co-expression of Islet1 and Hb9:eGFP (white arrows, f,g). Most Olig2+ progenitors do not co-express Islet1 or Hb9:eGFP (red arrows, i). Very rarely,
an Olig2+Hb9:GFP+Islet1+ cell is detected (green arrow, f-i). Scale bar 25 μm. (j) A higher proportion of MNs (percentage of total cells)
differentiated in wt non-Tg versus control or Tg SOD1G93A media (P<0.001) and, in Tg SOD1G93A CM versus control (P<0.01). (k) A higher
proportion of MN-progenitors differentiated in wt non-Tg versus control or Tg SOD1G93A media (P<0.001). Comparable proportions of MN-
progenitors differentiated in control and Tg SOD1G93A media. (l) Comparable proportions of MNs differentiated in wt non-Tg and Tg WTSOD1
CM and these were significantly higher versus control (P<0.001). (m) Slightly more MN-progenitors differentiated in wt non-Tg versus Tg WTSOD1
CM (P<0.05). Comparable proportions of MN-progenitors differentiated in control and Tg WTSOD1 CM. Values represent means ± s.e.m from n=4
or n=3 independent experiments (indicated in graphs), performed in triplicate, analysed by one-way ANOVA followed by Tukey’s post-test.
*P<0.05, **P<0.01, ***P<0.001.
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fect of wt non-Tg astrocyte CM is to increase the number
of MN progenitor cells. Importantly, moreover, culture
with wt non-Tg astrocyte CM appeared to result in a more
robust conversion of Olig2+ progenitors to MNs or sur-
vival of MNs. In the case of controls, approximately 8.8%
of Olig2+ progenitors differentiated to MNs, whereas with
wt non-Tg astrocyte CM, approximately 16.8% of Olig2+
progenitors differentiated to MNs. Thus, wt non-Tg astro-
cyte CM may promote the generation of differentiatedMNs in two ways: first, by increasing the numbers of pro-
genitors, and second, by supporting their robust differenti-
ation/survival.
In contrast to the effects of wt non-Tg astrocyte CM,
medium conditioned by astrocytes derived from transgenic
mice expressing mutant SOD1-G93A (Tg SOD1-G93A) did
not show a supportive effect on Olig2+ MN progenitors.
Quantitative analyses showed that in Tg SOD1-G93A CM,
the number of Olig2+ MN-progenitors was similar to those
in the control (p >0.05, not significant), but decreased
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littermate wt non-Tg CM (Figure 2k). Tg SOD1-G93A
astrocyte CM similarly appeared far less able to support
eGFP+ MNs, compared to wt non-Tg astrocyte CM. Quan-
titative analyses revealed a two-fold difference in the per-
centage of eGFP+ MNs in Tg SOD1-G93A CM compared
to the littermate wt non-Tg CM (p <0.001) (Figure 2j). Not-
ably, however, the efficiency of differentiation to MNs from
Olig2+ progenitors in Tg SOD1-G93A CM appears com-
parable to that in wt non-Tg astrocyte CM (differentiation/
survival coefficient of 13% which is closer to the wt non-Tg
astrocyte CM than to the control: see Methods). To deter-
mine whether Tg SOD1-G93A CM decreases the numbers
of MN progenitors and MNs by increasing apoptosis, indi-
cative of the presence of a toxic factor [15], we analysed
chromatin condensation and nuclear fragmentation after
DAPI-labelling [26]. Quantitative analyses revealed no sta-
tistically significant association of the number of apoptotic
cells with any of the three media (Additional file 1: Figure
S1). Taken together, these results indicate that, while CM
from wt non-Tg astrocytes is strongly supportive of both
Olig2+ MN progenitor cells and eGFP+ MNs, CM from Tg
SOD1-G93A astrocytes appears to lack, in particular, a
trophic support factor to motor neuron progenitors.
In order to confirm that the significant differences found
in the proportion of Olig2+ MN-progenitor cells and
eGFP+ MNs between the wt non-Tg astrocyte CM and
the SOD1-G93A or the control medium were indeed due
to the presence of the G93A mutation and not to the
presence of the transgene, a similar study was performed,
this time using conditioned medium from transgenic
astrocytes over-expressing human wild-type SOD1 (Tg
WTSOD1), or, for comparison, CM from their wt non-Tg
littermates. As expected, the percentage of eGFP+ MNs
detected after culture with either wt non-Tg or WTSOD1
CM was similar (p >0.05, not significant; Figure 2l), while
both media evoked a higher proportion of differentiated
MNs than control medium (Figure 2l; p <0.001; a two-
fold increase of eGFP+ MNs compared to the control;
coefficient of differentiation is 11% for control; 16% for
wt non-Tg; 18% for Tg WTSOD1). Similarly, there was a
significant difference in the percentage of Olig2+ MN-
progenitor cells in cultures grown in wt non-Tg astrocyte
CM compared to control medium (p <0.01; Figure 2m).
However, there was almost no difference in the proportion
of Olig2+ cells supported through wt non-Tg murine
astrocyte CM, compared to CM from Tg WTSOD1 litter-
mates (Figure 2m; p <0.05). The similar proportion of
Olig2+ progenitors and eGFP+ MNs generated in the
presence of wt non-Tg and Tg WTSOD1 astrocyte CM
(Figure 2l,m) suggests that the presence and over-
expression of the human transgene in mouse astrocytes is
not the reason for any observed differences in the num-
bers of eGFP+ MNs. Therefore, the difference in theproportion of eGFP+ MNs in the wt non-Tg and Tg
SOD1-G93A astrocyte CM is likely to be due to the effect
of the SOD1-G93A mutation.
Neither wild type astrocyte CM nor mutant SOD1G93A
astrocyte CM affects the generation of Lhx1/5+
interneurons from mouse ES cells
We next examined whether the observed effects of Tg
SOD1-G93A and wt non-Tg astrocyte CM were specific to
MN-progenitors and MNs or whether similar effects
might be observed with other types of neurons. Analysis
of Lhx1/5+/Hb9- interneurons (Lhx1/5 is the mammalian
orthologue of chick Lim1/2, recognised by the anti-Lim1/
2 antibody) [27,28] revealed that the proportion of inter-
neurons that differentiated in cultures was very similar for
all three types of media examined. Thus, Tg SOD1-G93A
CM, littermate wt non-Tg astrocyte CM and control
medium appeared to be equally supportive to interneu-
rons (p >0.05; Figure 3a,b). This comparative study sug-
gests that the supportive factors in wt non-Tg and Tg
WTSOD1 astrocyte CM that are lacking in SOD1-G93A
astrocyte CM may act only on MN progenitor cells and
therefore particularly affect differentiated MNs.
Discussion
Published studies over the last few years have demon-
strated negative effects of mutant SOD1 astrocytes on MN
survival [12-14,17] but no study has so far examined any
potential effects on MN progenitor cells. The question of
how astrocyte CM may impact on MN progenitors is im-
portant, both from the perspective of ex vivo differentiation
strategies and, from the perspective of adult neurogenesis,
since buffering of the niche from localised astrocytes may
affect survival and differentiation efficiency of the progeni-
tors. Here we demonstrate an impact of astrocyte CM on
both MN progenitors and MNs, and demonstrate that mu-
tant SOD1 astrocytes fail, particularly, to provide survival/
trophic support to MN progenitors.
Our study reveals markedly higher numbers of Olig2+
MN progenitor cells and eGFP+ MNs in wt non-Tg astro-
cyte CM and consistently lower numbers in littermate Tg
SOD1-G93A CM. In contrast, Tg WTSOD1 and littermate
wt non-Tg CM have similar effects on eGFP+ MNs and
Olig2+ MN-progenitors, indicating that our findings are
likely due to the presence of mutant SOD1-G93A, rather
than over-expressed SOD1 per se.
The significantly higher number of Olig2+ MN progeni-
tor cells in the wt non-Tg astrocyte CM supports the idea
that normal astrocytes favour MN development potentially
by secreting supportive and/or trophic factors that pro-
mote MN progenitors. The positive role of astrocytes in
promoting MN growth and maturation in in vitro cultures
is already established [29]. Wild-type and mutant SOD1
astrocytes produce substantial amounts of functionally-
Figure 3 Examination of the effect of astrocyte conditioned
media on interneurons derived from differentiation of mouse
embryonic stem cells. (a) Double-labelled fluorescence image of
culture grown in wt non-Tg astrocyte CM labelled for Lhx1/5
interneurons (red), Hb9:eGFP MNs (green) and DAPI for nuclei (blue).
Scale bar 50 μm. (b) Analysis of the number of interneurons in
control medium, wt non-Tg and Tg SOD1G93A CM. Data gathered
from 2 independent experiments, each condition examined in
triplicate and analysed by one-way ANOVA followed by Tukey’s
post-test. No significant differences in the proportion of interneurons
were found between the three media.
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MN survival. Such factors include trophic factors
(GDNF -glial-derived neurotrophic factor, NGF) [30,31],
pro-inflammatory/inflammatory proteins (iNOS -inducible
nitric oxide synthase, cystatin-C, interferon-α, prostaglandin-
D2) [32,33], proteases (complement 3α,β) and protease
inhibitors, carrier proteins (apolipoprotein E, IBP-2 -
insulin-like growth factor binding protein-2), extracellular
matrix binding proteins (cyclophilin-A) and anti-oxidant
proteins (peroxiredoxins) [34]. Our study extends current
knowledge by showing that astrocytes also positively affectMN progenitor cells, potentially governing Olig2+ cell-
proliferation or Olig2+ cell-survival.
Unlike wt non-Tg astrocyte CM, Tg SOD1-G93A astro-
cyte CM does not favour MN progenitor cell growth: simi-
lar numbers of Olig2+ cells are found in Tg SOD1-G93A
CM and in control non-conditioned medium. The relatively
high numbers of differentiated MNs found with SOD1-
G93A CM, compared to control non-conditioned medium,
however, suggests that the mutant astrocyte CM does sup-
port MN differentiation/survival. It is therefore likely that a
number of the aforementioned factors that are produced by
astrocytes and that affect MN survival are secreted in
the conditioned medium and are also able to affect MN
progenitor cell survival, growth or differentiation.
Our findings support a previous study that shows a halv-
ing in the number of primary and ES cell-derived MNs
when cultured in Tg SOD1-G93A astrocyte CM compared
to wt non-Tg astrocyte CM [15]. Our results differ from
this study, however, in that they provide no evidence for
MN death through increased apoptosis of MN progenitors
or MNs: nuclear fragmentation was not increased by
SOD1-G93A CM, nor do we observe a significant decrease
in Olig2+ MN progenitor cells or MNs in Tg SOD1-G93A
astrocyte CM compared to the baseline level in the pres-
ence of control non-conditioned medium. Why might our
findings differ from this study, that demonstrated neuro-
toxicity by SOD1-G93A astrocytes mediated through the
recruitment of the Bax-dependent death machinery? Not-
ably, in our study, we analysed the effects of SOD1-G93A
CM at an earlier time-point. Potentially, then, the neuro-
toxic effects of SOD1-G93A CM are realised later than the
effects we examine here. While we cannot exclude the pos-
sibility that cell-death (through non-apoptotic pathways)
contributes to the reduced numbers of MN progenitor cells,
our data indicate that the mutant SOD1-G93A in astrocytes
affects a secretory mechanism/product which renders the
CM less supportive/trophic to MN-progenitors, potentially
affecting either Olig2+ cell-proliferation or Olig2+ cell-
survival. Thus, the beneficial effect observed with wt non-Tg
CM is likely due to the presence of a supportive factor(s)
that is absent or reduced from the Tg SOD1-G93A CM.
We also determined whether the effects of Tg SOD1-
G93A and wt non-Tg astrocyte CM were specific to MNs
and their progenitor cells by examining the effect on Lhx1/
5+/Hb9- interneurons. Both the Tg SOD1-G93A and wt
non-Tg CM were as trophic/supportive to interneurons as
the control medium indicating that mutant SOD1-G93A in
astrocytes did not affect interneurons and that the effects of
wt non-Tg and Tg SOD1-G93A astrocyte CM were selective
for MNs and MN progenitor cells. This is in agreement
with Nagai et al. who reported no effects on primary spinal
GABAergic or dorsal root ganglion neurons and ES cell-
derived interneurons grown in SOD1-G93A compared to
non-Tg astrocyte CM [15].
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Astrocytes are actively implicated in the neurodegeneration
in ALS. The exact mechanisms by which mutant SOD1 in
astrocytes can exert negative effects on MNs and MN-
progenitors still remain obscure, although existing evidence
indicates that astrocytes exert their effects on MNs through
several different mechanisms. Our study extends current
knowledge by showing a negative effect of the SOD1-G93A
mutation on Olig2+ MN-progenitor cells, possibly reveal-
ing new mechanisms of MN loss at the early stages of MN
development.Methods
Antibodies
Primary antibodies used were: anti-Olig2 rabbit polyclonal
(Chemicon), anti-Lim1/2 (4F2) mouse monoclonal (Devel-
opmental Studies Hybridoma Bank), anti-Islet1 (4D5)
mouse monoclonal (Developmental Studies Hybridoma
Bank), anti-Hb9/MNR2 (5C10) mouse monoclonal (De-
velopmental Studies Hybridoma Bank), β3-tubulin (class 3
beta-tubulin) mouse monoclonal or rabbit polyclonal
(Covance), anti-Ki67 rabbit polyclonal (Novocastra). Sec-
ondary antibodies used were anti-rabbit IgG-Alexa 594
and anti-mouse IgG-Alexa 594 (Molecular Probes), anti-
mouse IgG-Cy5 (Jackson laboratories).Animal ethics statement
All experiments were conducted according to the Animal
(Scientific Procedures) Act 1986, under Project License 40/
3089 reviewed and approved by the University of Sheffield
Ethical Review Sub-Committee, and the UK Animal Proce-
dures Committee (London, UK). The UK Home Office
code of practice for the housing and care of animals used
in scientific procedures was followed. We adhere to the
ARRIVE guidelines for reporting animal research [35].Immunohistochemistry
Mouse embryos at E10.5 were washed with PBS and fixed
in 4% PFA for 2 hours at 4°C, then rinsed with PBS and in-
cubated in 0.2M phosphate buffer with 30% sucrose at 4°C
overnight. Whole mount embryos were sectioned in slices
of 15 μm thickness using a cryostat at −25°C. Slices were
collected on glass slides, allowed to dry for 30 min-1 hour,
then washed with PBS, permeabilised with PBS/1% goat
serum/0.1% Triton X-100 and incubated with primary
antibodies at 4°C overnight. Incubation with secondary
antibodies was performed at room temperature for 1 hour.
The specimens were mounted in Vectashield Mounting
medium with DAPI and sealed with cover glass. Micros-
copy was performed using ZEISS Axio Imager.Z1 micro-
scope and AxioVision 4.6.3 software.Immunocytochemistry
Cell cultures were fixed with 4% paraformaldehyde,
permeabilised with PBS/ 2% goat serum/ 0.2% Triton X-
100 and incubated with primary antibodies at 4°C over-
night. Incubation with secondary antibodies was performed
at room temperature for 1 hour and the specimens were
mounted in Vectashield Mounting medium with DAPI. A
ZEISS Axio Imager.Z1 microscope was used and images
were captured using AxioVision 4.6.3 software. Islet1+, β3-
tubulin+ and Olig2+ cells were counted in 44 random
fields and co-expression of the markers was estimated as a
percentage of Olig2+ cells. For apoptosis assessment of
Olig2+ and Hb9:eGFP+ cells, apoptotic nuclei exhibiting
chromatin condensation and nuclear fragmentation after
DAPI-labelling were counted in a total of 30 random fields
per condition. For the conditioned media experiments,
Olig2+, Hb9:GFP+ and Lhx1/5+ cells (the mammalian
orthologue of chick Lim1/2, recognised by the anti-Lim1/2
antibody) were counted in 30 random fields per technical
replica of each of the conditions (control, wt non-Tg or Tg)
and per experiment and calculated as the percentage of
total cells (DAPI nuclei) per field. The percentages calcu-
lated from similar conditions within each experiment were
pooled together. The mean percentages of positive cells for
each marker and per condition were statistically analysed.
Statistical analysis
The data used for the statistical analyses were collected
from n independent biological replicates as noted in the
figure legends. In each biological replica, there were 3
technical replicas per condition (control medium, trans-
genic or wild-type non-transgenic mouse). Ten random
fields per technical replica were used for cell counting.
Thus at least 30 random fields were used per condition
and per experiment; therefore at least 90 random fields
were counted in total. Each field contains between 250–
300 cells. Therefore for each experiment, a sample size of
at least 7500 cells was used per condition. Statistical ana-
lysis was performed using GraphPad Prism 5.0 software.
Data were examined and fitted a normal distribution and
therefore were analysed using one-way ANOVA followed
by Tukey’s multiple comparison post-test, with Confi-
dence Interval 95% and alpha=0.05. Differences were con-
sidered significant for P values less than 0.05. For apoptosis
assessment, association of the number of apoptotic cells
with the media was examined using the Chi-square test
with 95% Confidence Interval.
Calculation of differentiation/survival coefficient
For each condition (control, wt non-Tg or Tg condi-
tioned medium) the number of Olig2+ and eGFP+ cells
was used in the following formula:
Differentiation/survival coefficient= Y/X *100; where X
is the mean percentage of Olig2+ cells of the treatment
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The formula translates as follows: In a total of 100 cells,
X cells are Olig2+ and Y cells differentiate to eGFP+ cells.
Therefore, in 100 Olig2+ cells the proportion of cells to
differentiate/survive towards eGFP+ cells is Y/X *100.
Preparation of SHH-N protein
SHH-N protein containing culture supernatant was pre-
pared as described previously [36]. Briefly, 3 days post
transfection of a ShhN-pIRES2-eGFP construct into HEK/
293T cells, the culture supernatant was collected and con-
centrated up to 10× or 25× by repetitive centrifugation in
columns of a 10 kDa threshold (Amicon Bioseparations)
according to the manufacturer’s instructions.
Preparation of murine primary astrocyte cultures
Primary astrocyte cultures were prepared from the corti-
ces of SOD1-G93A (B6SJLTg(SOD1*G93A)1Gur/J pur-
chased from Jackson Laboratories),WT SOD1 and non-Tg
littermate neonate 1–2 day old (p1-p2) mice. The total
number of mice used were, eight Tg SOD1-G93A and ten
wt non-Tg mice from four litters, six Tg WTSOD1 and six
wt non-Tg from 3 litters. The cortices were stripped of
meninges, washed and triturated in Hank’s balanced salt
solution (HBSS) with Ca2+/Mg2+ containing 0.04% tryp-
sin (Sigma), 0.1 mg/ml collagenase (Calbiochem) and 0.05
mg/ml DNaseI (Sigma). Following trituration, the enzym-
atic process was terminated by addition of an equal vol-
ume of complete medium [Dulbecco’s modified Eagle’s
medium (DMEM, Cambrex), 10% heat inactivated fetal
calf serum (FCS, BioSera), 100 units/ml penicillin and 100
μg/ml streptomycin (Gibco)] and the cells plated in
complete medium [10% FCS, 2 mM L-glutamine, 100 U/ml
Penicillin and 100 μg/ml Streptomycin] in a T25 (P1). The
cell preparations were allowed to attach. After 48 hours,
the medium with any cell debris was removed, cells were
washed once with PBS and fresh complete medium was
added. Astrocytes and microglia were allowed to grow to
confluency for 2 weeks.
Purification of astrocytes from microglia
The overlying microglia cells were removed by shaking
overnight on a rotatory shaker (Weiss Gallenkamp) at 37°C
between 180-220 rpm. Pure astrocyte cultures were next
established by mild trypsinisation (0.25% trypsin and 1mM
EDTA in HBSS (−Ca/Mg), added in a ratio of 1:2 with
serum-free DMEM/F12), followed by trypsinisation with
2.5% trypsin in PBS and trituration up to single cells. Tryp-
sin was inactivated with complete medium and the sus-
pension was centrifuged. The astrocytes were plated in
complete medium in T25 flasks (P2) and allowed to
grow to confluency for 10 days before harvesting for
conditioned medium.Preparation of astrocyte conditioned medium
Conditioned medium was prepared by incubation with the
astrocytes. The maintenance medium was removed from
the cultures and astrocytes were rinsed with PBS. N2B27
medium (see below) was added and the medium was condi-
tioned for 48 hours. Conditioned medium was collected,
centrifuged to remove any cells present and stored at 4°C to
be used immediately.
Differentiation of mouse ES cells in monolayer culture
MNs expressing eGFP were derived from the transgenic
Hb9:eGFP mouse ES cell-line HBG3 [37] (generous gift
from Professor Thomas Jessell, Columbia University).
Mouse ES cells were removed from the flask by
trypsinisation, resuspended in mESC-medium [DMEM
(4.5 g/L glucose and 0.11 g/L sodium pyruvate), L-
glutamine (2 mM), penicillin/streptomycin (100 μg/ml)
(all from Gibco), 15% FCS (Globepharm) and 0.1 mM
β-mercaptoethanol (Sigma)] and plated on tissue cul-
ture plastic substrate pre-coated with 0.1% w/v gelatin
overnight. Mouse ES cells-medium was next replaced by
N2B27 (1:1) medium. N2 consisted of DMEM:F12, BSA
fraction-V (50 μg/ml, Gibco), insulin (25 μg/ml), transferrin
(100 μg/ml), progesterone (20 nM), putrescine (100 μM),
sodium selenite (20 nM) (all from Sigma), L-glutamine
(2 mM), penicillin/streptomycin (100 μg/ml). B27 consisted
of neurobasal medium (Gibco), B27 (1:50), L-glutamine
(2 mM), penicillin/streptomycin (100 μg/ml). The differen-
tiating cells were cultured in N2B27 for 7 days, RA
(0.1 μM) and SHH-N (1×) added on days 3 and 4. On day
7, the cells were trypsinised and replated on PDL (10 μg/ml)/
laminin (5 μg/ml) coated 8-well chamber slides at 5×104
cells/cm2 in control N2B27 or astrocyte conditioned N2B27
supplemented with bFGF (10 ng/ml) for 2 days. After 2
days, bFGF was withdrawn and fresh control or conditioned
N2B27 were added. The differentiation cultures were grown
for another 3 days, prior to immunocytochemical analysis.
Additional file
Additional file 1: Figure S1. Examination of the effect of astrocyte
conditioned media on the apoptosis of motor neuron-progenitor cells and
motor neurons. (a, b) The apoptotic nuclei of Olig2+ MN-progenitor cells (a)
and Hb9:eGFP+ MNs (b) were counted in three independent experiments in a
total of 30 random fields per condition. Statistically significant association of
the number of apoptotic cells with the media was examined using Chi-square
test with 95% Confidence Interval (alpha=0.05). There is no statistically
significant association between the level of apoptosis of Olig2+ cells (P value
0.2787) or eGFP+ MNs (P value 0.3028) with any of the three media. Apoptotic
Olig2+ cells are 3.98%, 3.22% and 4.51% of the total Olig2+ cells in Tg
SOD1G93A CM, wt non-Tg CM and control medium respectively. Apoptotic
eGFP+ MNs are 6.32%, 3.11% and 3.82% of the total eGFP+ MNs in Tg
SOD1G93A CM, wt non-Tg CM and control medium respectively.
Abbreviations
ALS: Amyotrophic lateral sclerosis; bHLH: basic Helix-Loop-Helix;
CM: Conditioned medium; ES cells: Embryonic stem cells; MN: Motor neuron;
Christou et al. BMC Neuroscience 2013, 14:126 Page 9 of 10
http://www.biomedcentral.com/1471-2202/14/126NGF: Nerve growth factor; non-Tg: non-transgenic; SOD1: Superoxide
dismutase-1; Tg: Transgenic; SVZ: Sub-ventricular zone; VZ: Ventricular zone;
Wt: Wild-type.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YAC designed and performed the experiments, performed the statistical
analyses, interpreted the results and contributed to the manuscript
preparation. KO and MP contributed to the design of the experiments,
interpretation of results and manuscript preparation. PJS was the grant
holder. PNM, MP and PJS supervised the study and contributed to the
manuscript preparation. All authors read and approved the final manuscript.
Acknowledgements
We thank Professor Thomas Jessell (Columbia University) for the HBG3 mESC
line. This study was supported by the Department of Neuroscience (PJ Shaw)
and the MRC Centre for Developmental and Biomedical Genetics (M Placzek)
of the University of Sheffield. PJS is supported as an NIHR Senior Investigator.
Author details
1Department of Neuroscience, Sheffield Institute for Translational
Neuroscience (SITraN), University of Sheffield, Sheffield, S10 2HQ, UK.
2Department of Infection and Immunity, Faculty of Medicine, Dentistry and
Health, University of Sheffield, Sheffield, S10 2HQ, UK. 3MRC Centre for
Developmental and Biomedical Genetics and Department of Biomedical
Science, University of Sheffield, Sheffield, S10 2RX, UK.
Received: 11 June 2013 Accepted: 9 October 2013
Published: 17 October 2013
References
1. Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS,
Miyamoto N, Showguchi-Miyata J, Okada Y, Singaraja R, et al: A gene
encoding a putative GTPase regulator is mutated in familial amyotrophic
lateral sclerosis 2. Nat Genet 2001, 29(2):166–173.
2. Kanekura K, Hashimoto Y, Niikura T, Aiso S, Matsuoka M, Nishimoto I: Alsin,
the product of ALS2 gene, suppresses SOD1 mutant neurotoxicity
through RhoGEF domain by interacting with SOD1 mutants. J Biol Chem
2004, 279(18):19247–19256.
3. Corrado L, Del Bo R, Castellotti B, Ratti A, Cereda C, Penco S, Soraru G,
Carlomagno Y, Ghezzi S, Pensato V, et al: Mutations of FUS gene in
sporadic amyotrophic lateral sclerosis. J Med Genet 2010, 47(3):190–194.
4. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde
C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, et al: TARDBP
mutations in individuals with sporadic and familial amyotrophic lateral
sclerosis. Nat Genet 2008, 40(5):572–574.
5. Corrado L, Ratti A, Gellera C, Buratti E, Castellotti B, Carlomagno Y, Ticozzi N,
Mazzini L, Testa L, Taroni F, et al: High frequency of TARDBP gene
mutations in Italian patients with amyotrophic lateral sclerosis.
Hum Mutat 2009, 30(4):688–694.
6. Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola
M, Geser F, Greene R, Lu MM, et al: Ataxin-2 intermediate-length
polyglutamine expansions are associated with increased risk for ALS.
Nature 2010, 466(7310):1069–1075.
7. Fernandez-Santiago R, Hoenig S, Lichtner P, Sperfeld AD, Sharma M, Berg D,
Weichenrieder O, Illig T, Eger K, Meyer T, et al: Identification of novel
Angiogenin (ANG) gene missense variants in German patients with
amyotrophic lateral sclerosis. J Neurol 2009, 256(8):1337–1342.
8. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M,
Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al:
Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of
C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron 2011,
72(2):245–256.
9. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Raphael
Gibbs J, Schymick JC, Laaksovirta H, Van Swieten JC, Myllykangas L, et al: A
hexanucleotide repeat expansion in C9ORF72 is the cause of
chromosome 9p21-linked ALS-FTD. Neuron 2011, 72(2):257–268.
10. Clement AM, Nguyen M, Roberts E, Garcia M, Boillee S, Rule M, McMahon
AP, Doucette W, Siwek D, Ferrante RJ, et al: Wild-type nonneuronal cellsextend survival of SOD1 mutant motor neurons in ALS mice.
Science 2003, 302(5642):113–117.
11. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW: Selective loss
of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis.
Ann Neurol 1995, 38:73–84.
12. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann
DH, Takahashi R, Misawa H, Cleveland DW: Astrocytes as determinants of
disease progression in inherited amyotrophic lateral sclerosis.
Nat Neurosci 2008, 11:251–253.
13. Pehar M, Cassina P, Vargas MR, Castellanos R, Viera L, Beckman JS, Estevez
AG, Barbeito L: Astrocytic production of nerve growth factor in motor
neuron apoptosis: implications for amyotrophic lateral sclerosis.
J Neurochemistry 2004, 89:464–473.
14. Ferraiuolo L, Higginbottom A, Heath PR, Barber S, Greenald D, Kirby J, Shaw
PJ: Dysregulation of astrocyte-motoneuron cross-talk in mutant
superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain 2011,
134(Pt 9):2627–2641.
15. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H,
Przedborski S: Astrocytes expressing ALS-linked mutated SOD1 release
factors selectively toxic to motor neurons. Nat Neurosci 2007, 10:615–622.
16. Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K: Non-cell
autonomous effect of glia on motor neurons in an embryonic stem-cell
based ALS model. Nat Neurosci 2007, 10:608–614.
17. Lepore AC, Rauck B, Dejea C, Pardo AC, Rao MS, Rothstein JD, Maragakis NJ:
Focal transplantation-based astrocyte replacement is neuroprotective in
a model of motor neuron disease. Nat Neurosci 2008, 11:1294–1301.
18. Pytte C, Yu YL, Wildstein S, George S, Kirn JR: Adult neuron addition to the
zebra finch song motor pathway correlates with the rate and extent of
recovery from botox-induced paralysis of the vocal muscles. J Neurosci
2011, 31(47):16958–16968.
19. Reimer MM, Norris A, Ohnmacht J, Patani R, Zhong Z, Dias TB, Kuscha V,
Scott AL, Chen Y-C, Rozov S, et al: Dopamine from the brain promotes
spinal motor neuron generation during development and adult
regeneration. Dev Cell 2013, 25(5):478–491.
20. Novitch BG, Wichterle H, Jessell TM, Sockanathan S: A requirement for
retinoic acid-mediated transcriptional activation in ventral neural
patterning and motor neuron specification. Neuron 2003, 40(1):81–95.
21. Lee S, Pfaff S: Synchronization of neurogenesis and motor neuron
specification by direct coupling of bHLH and homeodomain
transcription factors. Neuron 2003, 38(5):731–745.
22. Lee SK, Jurata LW, Funahashi J, Ruiz EC, Pfaff SL: Analysis of embryonic
motoneuron gene regulation: derepression of general activators
function in concert with enhancer factors. Development 2004,
131(14):3295–3306.
23. Novitch BG, Chen AI, Jessell TM: Coordinate regulation of motor neuron
subtype identity and pan-neuronal properties by the bHLH repressor
Olig2. Neuron 2001, 31(5):773–789.
24. Gaber ZB, Novitch BG: All the embryo's a stage, and Olig2 in its time
plays many parts. Neuron 2011, 69(5):833–835.
25. Lee SK, Lee B, Ruiz EC, Pfaff SL: Olig2 and Ngn2 function in opposition to
modulate gene expression in motor neuron progenitor cells. Genes Dev
2005, 19(2):282–294.
26. Doonan F, Cotter TG: Morphological assessment of apoptosis.
Methods 2008, 44(3):200–204.
27. Gross MK, Dottori M, Goulding M: Lbx1 specifies somatosensory association
interneurons in the dorsal spinal cord. Neuron 2002, 34(4):535–549.
28. Muller T, Brohmann H, Pierani A, Heppenstall PA, Lewin GR, Jessell TM,
Birchmeier C: The homeodomain factor lbx1 distinguishes two major
programs of neuronal differentiation in the dorsal spinal cord.
Neuron 2002, 34(4):551–562.
29. Ullian EM, Harris BT, Wu A, Chan JR, Barres BA: Schwann cells and
astrocytes induce synapse formation by spinal motor neurons in culture.
Mol Cell Neurosci 2004, 25:241–251.
30. Suzuki M, McHugh J, Tork C, Shelley B, Klein SM, Aebischer P, Svendsen CN:
GDNF secreting human neural progenitor cells protect dying motor
neurons, but not their projection to muscle, in a rat model of familial
ALS. PLoS ONE 2007, 2(8):e689.
31. Pehar M, Cassina P, Vargas MR, Castellanos R, Viera L, Beckman JS, Estevez
AG, Barbeito L: Astrocytic production of nerve growth factor in motor
neuron apoptosis: implications for amyotrophic lateral sclerosis.
J Neurochem 2004, 89(2):464–473.
Christou et al. BMC Neuroscience 2013, 14:126 Page 10 of 10
http://www.biomedcentral.com/1471-2202/14/12632. Marchetto MC, Muotri AR, Mu Y, Smith AM, Cezar GG, Gage FH: Non-cell-
autonomous effect of human SOD1 G37R astrocytes on motor neurons
derived from human embryonic stem cells. Cell Stem Cell 2008, 3(6):649–657.
33. Di Giorgio FP, Boulting GL, Bobrowicz S, Eggan KC: Human embryonic
stem cell-derived motor neurons are sensitive to the toxic effect of glial
cells carrying an ALS-causing mutation. Cell Stem Cell 2008, 3(6):637–648.
34. Lafon-Cazal M, Adjali O, Galeotti N, Poncet J, Jouin P, Homburger V,
Bockaert J, Marin P: Proteomic analysis of astrocytic secretion in the
mouse. Comparison with the cerebrospinal fluid proteome. J Biol Chem
2003, 278:24438–24448.
35. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG: Improving
bioscience research reporting: the ARRIVE guidelines for reporting
animal research. PLoS Biol 2010, 8(6):e1000412.
36. Ohyama K, Ellis P, Kimura S, Placzek M: Directed differentiation of neural cells to
hypothalamic dopaminergic neurons. Development 2005, 132(23):5185–5197.
37. Wichterle H, Lieberam I, Porter JA, Jessell TM: Directed differentiation of
embryonic stem cells into motor neurons. Cell 2002, 110(3):385–397.
doi:10.1186/1471-2202-14-126
Cite this article as: Christou et al.: Wild-type but not mutant SOD1
transgenic astrocytes promote the efficient generation of motor neuron
progenitors from mouse embryonic stem cells. BMC Neuroscience
2013 14:126.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
